CRDMO
WuXi AppTec Sells China-Based Clinical Research Units to Hillhouse Investment Management
WuXi AppTec; clinical services; China-based; sale; Hillhouse Investment Management; WuXi Clinical; WuXi MedKey; CRDMO strategy
WuXi AppTec Divests China Clinical Services to Hillhouse Capital, Refocuses on Manufacturing Business
WuXi AppTec; Hillhouse Capital; divestment; clinical research services; CRDMO; manufacturing; China; WuXi Clinical; MedKey
WuXi Biologics’ ADC Spinout Sees Revenue Surge Amid Biosecure Threat
WuXi Biologics, ADC spinout, revenue jump, Biosecure risk, CRDMO, bioconjugate market